enGene, Inc. and Forbion European Acquisition Corp. Announce Business Combination Agreement to Create Biotechnology Company

enGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.

NewsGuest UserMay 24, 2023BIOOQuébecenGene, enGene Holdings Inc, Financing